Top developments in 2018 in treating breast cancer
The FDA has approved the drug Olaparib (Lynparza®) For the treatment of stage 4 metastatic breast cancer patients, whose growth expresses mutations in the BRCA gene. The approval was given…
The FDA has approved the drug Olaparib (Lynparza®) For the treatment of stage 4 metastatic breast cancer patients, whose growth expresses mutations in the BRCA gene. The approval was given…